Charles River Laboratories Continues Commitment to Oncology Drug Discovery

Charles River Laboratories International, Inc. (NYSE: CRL) today
announced new additions to the Tumor
Model Compendium. Charles Rivera??s Compendium provides access to a
comprehensive collection of well-established tumor models for
early-stage oncology research.

The most recent Compendium update adds gastric and liver models, as well
as new molecular data for leukemia, liver cancer, lymphoma, breast
cancer and ovarian cancer. The newest additions to the Compendium
provide oncology researchers access to data that allows them to identify
the most appropriate tumor models, leading to a more targeted study
design from the start, saving time and money on the path to the clinic.

The Compendium includes tumor models from a wide range of tumor subtypes
for both in vivo and in vitro oncology research, including patient-derived
xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic

Presence at Scientific Conferences

The Compendium is just one example of Charles Rivera??s commitment to
oncology research. Charles River experts presented four posters at the
Society for Immunotherapya??s (SITC) 33rd Annual Meeting and
will present nine posters at the European Organisation for Research and
Treatment of Cancer (EORTC) Conference in Dublin, Ireland.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Май 2022    »